Role of oral teriflunomide in the management of multiple sclerosis

被引：14
|
作者：
Tanasescu, Radu [1 ,2 ]
Evangelou, Nikos [1 ]
Constantinescu, Cris S. [1 ]
机构：
[1] Univ Nottingham, Acad Div Clin Neurol, Nottingham NG7 2RD, England
[2] Carol Davila Univ Med & Pharm, Colentina Hosp, Dept Neurol, Bucharest, Romania
来源：
NEUROPSYCHIATRIC DISEASE AND TREATMENT | 2013年 / 9卷
关键词：
teriflunomide; multiple sclerosis; oral drugs; clinical trials; PLACEBO-CONTROLLED TRIAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; NITRIC-OXIDE SYNTHASE; RHEUMATOID-ARTHRITIS; A77; 1726; TYROSINE PHOSPHORYLATION; CONTROLLED PHASE-3; T-CELLS; LEFLUNOMIDE; INHIBITION;
D O I：
10.2147/NDT.S31248
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The landscape of the treatment of relapsing-remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing-remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor with selective immunomodulatory and immunosuppressive properties that have shown consistent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the mechanisms of action and efficacy and safety results from clinical trials with this drug. The role of teriflunomide in the treatment of relapsing-remitting multiple sclerosis is discussed.
引用
收藏
页码：539 / 553
页数：15
相关论文
共 50 条
  • [1] Teriflunomide for oral therapy in multiple sclerosis
    Papadopoulou, Athina
    Kappos, Ludwig
    Sprenger, Till
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (06) : 617 - 628
  • [2] Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
    Sartori, Arianna
    Carle, Dawn
    Freedman, Mark S.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 1019 - 1027
  • [3] Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
    O'Connor, Paul
    Wolinsky, Jerry S.
    Confavreux, Christian
    Comi, Giancarlo
    Kappos, Ludwig
    Olsson, Tomas P.
    Benzerdjeb, Hadj
    Truffinet, Philippe
    Wang, Lin
    Miller, Aaron
    Freedman, Mark S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1293 - 1303
  • [4] Teriflunomide for multiple sclerosis
    He, Dian
    Xu, Zhu
    Dong, Shuai
    Zhang, Hong
    Zhou, Hongyu
    Wang, Lu
    Zhang, Shihong
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12):
  • [5] TERIFLUNOMIDE: NEW ORAL IMMUNMODULANT DRUG IN THERAPY OF MULTIPLE SCLEROSIS
    Bencsik Krisztina
    Rozsa Csilla
    Vecsei Laszlo
    [J]. IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2015, 68 (3-4): : 79 - 87
  • [6] Teriflunomide for multiple sclerosis
    He, Dian
    Zhang, Chao
    Zhao, Xia
    Zhang, Yifan
    Dai, Qingqing
    Li, Yuan
    Chu, Lan
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (03):
  • [7] Teriflunomide for the Treatment of Multiple Sclerosis
    Oh, Jiwon
    O'Connor, Paul W.
    [J]. SEMINARS IN NEUROLOGY, 2013, 33 (01) : 45 - 55
  • [8] Teriflunomide for treatment of multiple sclerosis
    Warnke, C.
    Hoerste, G. Meyer Zu
    Menge, T.
    Stueve, O.
    Hartung, H. -P.
    Wiendl, H.
    Kieseier, B. C.
    [J]. NERVENARZT, 2013, 84 (06): : 724 - 731
  • [9] Teriflunomide for the treatment of multiple sclerosis
    Warnke, Clemens
    Stueve, Olaf
    Kieseier, Bernd C.
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 : S90 - S94
  • [10] Emerging oral immunomodulating agents - focus on teriflunomide for the treatment of multiple sclerosis
    Nwankwo, Enyioma
    Allington, Douglas R.
    Rivey, Michael P.
    [J]. DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2012, 2 : 15 - 28
12345